Wellington Management Group LLP Has $47.46 Million Holdings in Artivion, Inc. (NYSE:AORT)

Wellington Management Group LLP grew its position in shares of Artivion, Inc. (NYSE:AORT) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,660,081 shares of the company’s stock after acquiring an additional 3,817 shares during the quarter. Wellington Management Group LLP owned about 3.96% of Artivion worth $47,462,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of AORT. The Manufacturers Life Insurance Company increased its stake in Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock valued at $522,000 after purchasing an additional 4,295 shares in the last quarter. FMR LLC increased its position in shares of Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after acquiring an additional 25,176 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Artivion by 543.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock worth $761,000 after acquiring an additional 24,130 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Artivion during the 3rd quarter valued at about $960,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Trading Down 3.7 %

Shares of Artivion stock opened at $23.24 on Friday. The firm has a market cap of $977.20 million, a PE ratio of -1,162.00 and a beta of 1.65. Artivion, Inc. has a 1 year low of $19.36 and a 1 year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a fifty day moving average price of $26.93 and a 200-day moving average price of $27.61.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other news, insider John E. Davis sold 15,100 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the sale, the insider now owns 208,778 shares of the company’s stock, valued at $4,929,248.58. The trade was a 6.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the sale, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,799 shares of company stock worth $2,356,223. Insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on AORT. Needham & Company LLC dropped their target price on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.